
|Articles|April 1, 2004
Levofloxacin 1.5% earns FDA approval
Minneapolis, MN-The new fluoroquinolone, levofloxacin 1.5% ophthalmic solution (IQUIX, Santen), has received FDA approval to be marketed for the treatment of bacterial corneal ulcer. The approval brings with it a milestone as the first current-generation fluoroquinolone with an indication for use in the management of that sight-threatening condition, explained Richard L. Lindstrom, MD.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Innovations in glaucoma poised for breakthrough in 2026 (and what might hold them back)
2
FDA Clears IND application for GenEditBio’s GEB-101 in TGFBI corneal dystrophy
3
Rates of retinal layer thinning predict visual field progression in glaucoma
4
The Residency Report: When can adalimumab be stopped in JIA-associated uveitis
5












































